Multiple Dose Study of Aducanumab (BIIB037) (Recombinant, Fully Human Anti-Aβ IgG1 mAb) in Participants With Prodromal or Mild Alzheimer's Disease

NCT01677572 · clinicaltrials.gov ↗
PHASE1
Phase
TERMINATED
Status
197
Enrollment
INDUSTRY
Sponsor class

Stopped Study was discontinued based on futility analysis conducted on Phase 3 trials (NCT02477800 and NCT02484547) and not based on safety concerns.

Conditions

Interventions

Sponsor

Biogen